Healthcare provider profile · identity verified

Mark Brown, MD

Internal Medicine · PHOENIXVILLE, PA · NPI 1467491050

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	966	252
Lisinopril	Lisinopril	583	164
Levothyroxine Sodium	Levothyroxine Sodium	537	139
Amlodipine Besylate	Amlodipine Besylate	525	138
Rosuvastatin Calcium	Rosuvastatin Calcium	376	113
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	342	83
Losartan Potassium	Losartan Potassium	322	92
Pantoprazole Sodium	Pantoprazole Sodium	301	91
Simvastatin	Simvastatin	276	79
Metoprolol Succinate	Metoprolol Succinate	234	68
Metformin Hcl	Metformin Hcl	232	66
Escitalopram Oxalate	Escitalopram Oxalate	230	58
Omeprazole	Omeprazole	226	55
Hydrochlorothiazide	Hydrochlorothiazide	213	54
Lorazepam	Lorazepam	183	41
Metoprolol Tartrate	Metoprolol Tartrate	176	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	170	38
Glimepiride	Glimepiride	168	41
Metformin Hcl Er	Metformin Hcl	165	44
Gabapentin	Gabapentin	158	39
Furosemide	Furosemide	143	37
Tramadol Hcl	Tramadol Hcl	137	39
Alprazolam	Alprazolam	131	29
Azithromycin	Azithromycin	131	101
Allopurinol	Allopurinol	129	39
Sertraline Hcl	Sertraline Hcl	115	33
Tamsulosin Hcl	Tamsulosin Hcl	112	34
Clopidogrel	Clopidogrel Bisulfate	108	28
Eliquis	Apixaban	100	29
Prednisone	Prednisone	98	64
Trazodone Hcl	Trazodone Hcl	81	21
Xarelto	Rivaroxaban	76	20
Clonazepam	Clonazepam	74	suppressed
Glyxambi	Empagliflozin/Linagliptin	74	15
Spironolactone	Spironolactone	67	15
Bisoprolol Fumarate	Bisoprolol Fumarate	63	12
Ezetimibe	Ezetimibe	63	19
Famotidine	Famotidine	63	18
Montelukast Sodium	Montelukast Sodium	63	14
Januvia	Sitagliptin Phosphate	61	14
Duloxetine Hcl	Duloxetine Hcl	60	18
Zolpidem Tartrate	Zolpidem Tartrate	60	15
Carvedilol	Carvedilol	59	18
Atenolol	Atenolol	55	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	13
Albuterol Sulfate Hfa	Albuterol Sulfate	51	26
Ciprofloxacin Hcl	Ciprofloxacin Hcl	49	36
Alendronate Sodium	Alendronate Sodium	48	11
Jardiance	Empagliflozin	48	15
Donepezil Hcl	Donepezil Hcl	47	11
Fluticasone Propionate	Fluticasone Propionate	45	17
Clonidine Hcl	Clonidine Hcl	44	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	43	11
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	42	12
Meloxicam	Meloxicam	38	18
Citalopram Hbr	Citalopram Hydrobromide	37	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	suppressed
Ipratropium Bromide	Ipratropium Bromide	35	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	34	suppressed
Potassium Chloride	Potassium Chloride	33	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	32	suppressed
Labetalol Hcl	Labetalol Hcl	32	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	26
Dicyclomine Hcl	Dicyclomine Hcl	30	suppressed
Myrbetriq	Mirabegron	30	suppressed
Valsartan	Valsartan	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Warfarin Sodium	Warfarin Sodium	29	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	suppressed
Finasteride	Finasteride	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	19
Buspirone Hcl	Buspirone Hcl	25	suppressed
Colchicine	Colchicine	25	13
Triamcinolone Acetonide	Triamcinolone Acetonide	25	16
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	23	21
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Jantoven	Warfarin Sodium	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Klor-Con M20	Potassium Chloride	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Torsemide	Torsemide	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Diazepam	Diazepam	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	13
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Sotalol	Sotalol Hcl	18	suppressed
Amoxicillin	Amoxicillin	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Latanoprost	Latanoprost	17	suppressed
Risperidone	Risperidone	17	suppressed
Calcitriol	Calcitriol	16	suppressed
Flecainide Acetate	Flecainide Acetate	16	suppressed
Ramipril	Ramipril	16	suppressed
Scopolamine	Scopolamine	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Dofetilide	Dofetilide	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Cephalexin	Cephalexin	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Creon	Lipase/Protease/Amylase	12	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	12	suppressed
Invokamet	Canagliflozin/Metformin Hcl	12	suppressed
Nystatin	Nystatin	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error